Project Grant R01MH113564

This federal Project Grant award, valued at $189,540, was issued by the National Institute of Mental Health (NIMH) under the Mental Health Research Grants (CFDA 93.242) program. The grant will support research at the University of Pittsburgh to characterize the independent and additive effects of schizophrenia and cannabis use on cannabinoid CB1 receptor expression and signaling in the brain, and the resulting impact on working memory. The research will utilize cross-species analyses,...

This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $177,110 to the Cambridge Public Health Commission (doing business as Cambridge Health Alliance) to study the impact of cannabis legalization and commercialization on substance use and mental health outcomes among individuals with psychosis. The award will fund a multi-year research project that utilizes quasi-experimental...

This Project Grant award of $1,383,618 from the National Institute on Drug Abuse (NIDA) under CFDA Program 93.279 - Drug Use and Addiction Research Programs supports research to investigate the microglia-mediated adverse effects of cannabis (specifically Delta-9-tetrahydrocannabinol or THC) on prefrontal cortex maturation and cognitive function during adolescence. The research aims to: 1) identify the time course of cannabinoid receptor type 1 (CNR1)-mediated molecular and morphological...

The National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded a $621,186 Project Grant to the University of Wisconsin - Milwaukee (UWM). This 5-year grant, effective July 1, 2025, will fund a longitudinal study examining the impact of circulating endocannabinoid levels on neurocognition, impulsivity, and early cannabis use patterns in 2,000 youth enrolled in the Adolescent Brain Cognitive Development (ABCD) study. The research aims to...

This federal Project Grant award from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), provides $3,085,041 to the University of Pittsburgh to conduct longitudinal research on adolescent brain maturation and its relationship to psychopathology. The key objectives are to: Examine neuropil growth/contraction using 3D whole-brain phosphorus magnetic resonance spectroscopy (31P MRS) Elucidate alterations in multiple modalities of brain...

This Project Grant award from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), will fund a research study to examine in vivo brain energetics in schizophrenia. The $254,250 award will support a study to utilize [18F]BCPP-EF Positron Emission Tomography (PET) and Phosphorus Magnetic Resonance Spectroscopy (31P-MRS) to assess mitochondrial complex I function and oxidative phosphorylation in the dorsolateral prefrontal cortex of 10...

The National Institute of Mental Health (NIMH) awarded a $760,143 Project Grant (CFDA 93.242 - Mental Health Research Grants) to the University of Maryland, Baltimore to conduct research on the role of acetylcholine and cannabinoid signaling in working memory and motivation. The 5-year project, titled "Endocannabinoid Control of Cholinergic Transmission and the Pursuit of Reward," aims to investigate how the interaction between acetylcholine and cannabinoid type 1 receptors in the...

This $441,000 federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will support research at Yale University to investigate the molecular changes in the brain that link cannabis use disorder and major depressive disorder. The researchers will use innovative single-cell genomics to identify transcriptomic and chromatin alterations in two key brain regions from 120 donors with cannabis use disorder, major...

This Project Grant award from the National Institute of Mental Health (NIMH), under CFDA 93.242 - Mental Health Research Grants program, provides $665,508 to the Centre for Addiction and Mental Health (CAMH) in Canada to conduct a multi-center, randomized clinical trial. The goal is to develop a clozapine decision support tool based on biomarkers to improve outcomes for first-episode psychosis patients who do not respond well to conventional first-line antipsychotics. The study will characterize...

This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to investigate the impact of prenatal exposure to cannabis on childhood adiposity and cardiometabolic health outcomes. The $234,000 award, with a performance period from August 2024 to July 2026, will support a study using a well-characterized observational cohort in Colorado to measure the levels of delta-9-tetrahydrocannabinol (D9-THC) and...